Determining true HER2 gene status in breast cancers with polysomy by using alternative chromosome 17 reference genes: Implications for anti-HER2 targeted therapy

Journal of Clinical Oncology

Volumn 29, Issue 31, 2011, Pages 4168-4174

  Tse, Chun Hing ^a   Hwang, Harry C ^a   Goldstein, Lynn C ^a   Kandalaft, Patricia L ^a   Wiley, Jesse C ^b   Kussick, Steven J ^a,b   Gown, Allen M ^a,c  

^a PHENOPATH LABORATORIES   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEIN P53; RETINOIC ACID RECEPTOR ALPHA;

ARTICLE; BREAST CANCER; CHROMOSOME 17; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DOSAGE; GENE PROBE; GENE TARGETING; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; POLYSOME; PRIORITY JOURNAL; SMITH MAGENIS SYNDROME;

ADULT; AGED; ALGORITHMS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHROMOSOMES, HUMAN, PAIR 17; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; PHOSPHOPROTEINS; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 80755166082     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.36.0107     Document Type: Article

References (37)

1. Lal P, Salazar PA, Hudis CA, et al.: HER-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization: A single-institution experience of 2,279 cases and comparison of dual-color and single-color scoring. Am J Clin Pathol 121:631-636, 2004 (Pubitemid 38533994)
2. Owens MA, Horten BC, Da Silva MM: HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer 5:63-69, 2004 (Pubitemid 38821193)
3. Yaziji H, Goldstein LC, Barry TS, et al.: HER-2 testing in breast cancer using parallel tissue-based methods. JAMA 291:1972-1977, 2004
4. Tandon AK, Clark GM, Chamness GC, et al.: HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol 7:1120-1128, 1989
5. Sørlie T, Perou CM, Tibshirani R, et al.: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98:10869-10874, 2001 (Pubitemid 32878711)
6. Sorlie T, Tibshirani R, Parker J, et al.: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 100:8418-8423, 2003 (Pubitemid 36842560)
7. Villman K, Sjöström J, Heikkilä R, et al.: TOP2A and HER2 gene amplification as predictors of response to anthracycline treatment in breast cancer. Acta Oncol 45:590-596, 2006 (Pubitemid 44167211)
8. Pritchard KI, Shepherd LE, O'Malley FP, et al.: HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 354:2103-2111, 2006 (Pubitemid 43736610)
9. Cardoso F, Durbecq V, Larsimont D, et al.: Correlation between complete response to anthracycline-based chemotherapy and topoisomerase II-alpha gene amplification and protein overexpression in locally advanced/ metastatic breast cancer. Int J Oncol 24:201-209, 2004
10. Thor AD, Berry DA, Budman DR, et al.: erbB-2, p53, and efficacy of adjuvant therapy in lymph nodepositive breast cancer. J Natl Cancer Inst 90:1346-1360, 1998 (Pubitemid 28439959)
11. Ménard S, Valagussa P, Pilotti S, et al.: Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables. J Clin Oncol 19:329-335, 2001 (Pubitemid 32112843)
12. De Laurentiis M, Arpino G, Massarelli E, et al.: A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res 11:4741-4748, 2005 (Pubitemid 41557193)
13. Vogel CL, Cobleigh MA, Tripathy D, et al.: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719-726, 2002 (Pubitemid 34111379)
14. Slamon D, Pegram M: Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. Semin Oncol 28:13-19, 2001
15. Cobleigh MA, Vogel CL, Tripathy D, et al.: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639-2648, 1999 (Pubitemid 29415219)
16. Piccart-Gebhart MJ, Procter M, Leyland- Jones B, et al.: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672, 2005 (Pubitemid 41464705)
17. Romond EH, Perez EA, Bryant J, et al.: Trastuzumab plus adjuvant chemotherapy for operable HER2- positive breast cancer. N Engl J Med 353:1673-1684, 2005 (Pubitemid 41464706)
18. Finn RS, Press MF, Dering J, et al.: Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment in HER2- negative or unknown metastatic breast cancer. J Clin Oncol 27:3908-3915, 2009
19. Kaufman B, Trudeau M, Awada A, et al.: Lapatinib monotherapy in patients with HER2- overexpressing relapsed or refractory inflammatory breast cancer: Final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study. Lancet Oncol 10:581-588, 2009
20. Zhou X, Cella D, Cameron D, et al.: Lapatinib plus capecitabine versus capecitabine alone for HER2+(ErbB2+) metastatic breast cancer: Quality-of-life assessment. Breast Cancer Res Treat 117:577-589, 2009
21. Wolff AC, Hammond ME, Schwartz JN, et al.: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118-145, 2007 (Pubitemid 350003059)
22. Wolff AC, Hammond ME, Schwartz JN, et al.: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 131:18-43, 2007 (Pubitemid 46174133)
23. Fukushige S, Matsubara K, Yoshida M, et al.: Localization of a novel v-erbB-related gene, c-erbB-2, on human chromosome 17 and its amplification in a gastric cancer cell line. Mol Cell Biol 6:955-958, 1986 (Pubitemid 16135959)
24. Micale MA, Visscher DW, Gulino SE, et al.: Chromosomal aneuploidy in proliferative breast disease. Hum Pathol 25:29-35, 1994 (Pubitemid 24051821)
25. Jimenez RE, Wallis T, Tabasczka P, et al.: Determination of Her-2/Neu status in breast carcinoma: Comparative analysis of immunohistochemistry and fluorescent in situ hybridization. Mod Pathol 13:37-45, 2000 (Pubitemid 30077902)
26. Moelans CB, de Weger RA, van Diest PJ: Absence of chromosome 17 polysomy in breast cancer: Analysis by CEP17 chromogenic in situ hybridization and multiplex ligation-dependent probe amplification. Breast Cancer Res Treat 120:1-7, 2010
27. Yeh IT, Martin MA, Robetorye RS, et al.: Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event. Mod Pathol 22:1169-1175, 2009
28. Viale G: Be precise! The need to consider the mechanisms for CEP17 copy number changes in breast cancer. J Pathol 219:1-2, 2009
29. Marchiò C, Lambros MB, Gugliotta P, et al.: Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis. J Pathol 219:16-24, 2009
30. Vranic S, Teruya B, Repertinger S, et al.: Assessment of HER2 gene status in breast carcinomas with polysomy of chromosome 17. Cancer 117:48-53, 2011
31. Perez EA, Reinholz MM, Hillman DW, et al.: HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial. J Clin Oncol 28:4307-4315, 2010
32. Gown AM, Goldstein LC, Barry TS, et al.: High concordance between immunohistochemistry and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized IHC scoring system. Mod Pathol 21:1271-1277, 2008
33. Visscher DW, Wallis T, Ritchie CA: Detection of chromosome aneuploidy in breast lesions with fluorescence in situ hybridization: Comparison of whole nuclei to thin tissue sections and correlation with flow cytometric DNA analysis. Cytometry 21:95-100, 1995
34. Genest DR: Partial hydatidiform mole: Clinicopathological features, differential diagnosis, ploidy and molecular studies, and gold standards for diagnosis. Int J Gynecol Pathol 20:315-322, 2001
35. Watters AD, Going JJ, Cooke TG, et al.: Chromosome 17 aneusomy is associated with poor prognostic factors in invasive breast carcinoma. Breast Cancer Res Treat 77:109-114, 2003 (Pubitemid 36197611)
36. Vanden Bempt I, Van Loo P, Drijkoningen M, et al.: Polysomy 17 in breast cancer: Clinicopathologic significance and impact on HER-2 testing. J Clin Oncol 26:4869-4874, 2008
37. Troxell ML, Bangs CD, Lawce HJ, et al.: Evaluation of Her-2/neu status in carcinomas with amplified chromosome 17 centromere locus. Am J Clin Pathol 126:709-716, 2006 (Pubitemid 44707621)